Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2+ breast cancer

1 Oct 2023

Abstract excerpt

Patients with early-stage HER2-overexpressing breast cancer struggle with treatment resistance in 20%–40% of cases. More information is needed to predict HER2 therapy response and resistance in vivo . In this study, we perform (phospho)proteomics analysis of pre-treatment HER2 + needle biopsies of early-stage invasive breast cancer to identify molecular signatures predictive of treatment response to trastuzumab,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Biosensing Techniques and Applications
Share to Advanced Proteomics Techniques and Applications
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37794585
DOI: 10.1016/j.xcrm.2023.101203

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2+ breast cancerPMID 37794585Read ↗

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts responseSemantic proximity Read ↗

The Proteomic Landscape of Triple-Negative Breast CancerSemantic proximity Read ↗

Microscaled Proteogenomic Methods for Precision OncologySemantic proximity Read ↗

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancerSemantic proximity Read ↗

Sensitive and Specific Early-Stage Breast Cancer Detection using Deep Proteome Profiling from PlasmaSemantic proximity Read ↗

Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatmentSemantic proximity Read ↗

“Omics” of HER2-Positive Breast CancerSemantic proximity Read ↗

Discovery of Proteins Responsible for Resistance to Three Chemotherapy Drugs in Breast Cancer Cells Using Proteomics and Bioinformatics AnalysisSemantic proximity Read ↗

Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancerSemantic proximity Read ↗

Profiling protein post-translational modifications in plasma-derived extracellular vesicles as fingerprints for breast cancer subtypesSemantic proximity Read ↗

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read ↗

Profiling Protein Post-Translational Modifications in Plasma-derived Extracellular Vesicles as Fingerprints for Breast Cancer SubtypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.